HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation.

Abstract
Autophagy has recently emerged as a significant mechanism in cancer treatment. Although gemcitabine and/or ionizing radiation are important modalities in the treatment of pancreatic cancer, the contribution of autophagy in such treatment has not been fully elucidated. This study investigated the role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. To evaluate the effect of gemcitabine and/or ionizing radiation on autophagy, several human pancreatic cancer cell lines were used. The treatment of pancreatic cancer cell cultures in vitro and in vivo with gemcitabine and ionizing radiation resulted in synergistic cytotoxicity. After treatment with gemcitabine, the autophagy-related protein light chain 3-II (LC3-II) was upregulated. When gemcitabine was combined with ionizing radiation treatment, LC3-II upregulation was enhanced. In addition, electron microscopy of pancreatic cancer cells treated with gemcitabine and/or ionizing radiation detected the induction of autophagy. The blockage of autophagy by 3-methyladenine indicated that autophagy contributed to cell death after gemcitabine treatment and enhanced its cytotoxicity. The inhibitory effect and immune reactivity of the autophagy-related proteins LC3 and beclin-1 were the strongest after the combination treatment. In conclusion, these results suggest that autophagy can be activated by gemcitabine and/or ionizing radiation in the treatment of pancreatic cancer cells and that activated autophagy plays a role in cancer suppression. These findings may have important implications for future therapeutic strategies using gemcitabine and ionizing radiation against pancreatic cancer.
AuthorsHideyo Mukubou, Toshiaki Tsujimura, Ryohei Sasaki, Yonson Ku
JournalInternational journal of oncology (Int J Oncol) Vol. 37 Issue 4 Pg. 821-8 (Oct 2010) ISSN: 1791-2423 [Electronic] Greece
PMID20811703 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • Apoptosis Regulatory Proteins
  • BECN1 protein, human
  • Beclin-1
  • MAP1LC3A protein, human
  • Membrane Proteins
  • Microtubule-Associated Proteins
  • Deoxycytidine
  • 3-methyladenine
  • Adenine
  • Gemcitabine
Topics
  • Adenine (analogs & derivatives, pharmacology)
  • Animals
  • Antimetabolites, Antineoplastic (pharmacology)
  • Apoptosis Regulatory Proteins (metabolism)
  • Autophagy (drug effects, radiation effects)
  • Beclin-1
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Survival
  • Chemotherapy, Adjuvant
  • Deoxycytidine (analogs & derivatives, pharmacology)
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Humans
  • Immunohistochemistry
  • Male
  • Membrane Proteins (metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Microscopy, Electron, Scanning
  • Microtubule-Associated Proteins (metabolism)
  • Pancreatic Neoplasms (drug therapy, metabolism, pathology, radiotherapy)
  • Radiotherapy, Adjuvant
  • Time Factors
  • Tumor Burden
  • Up-Regulation
  • Xenograft Model Antitumor Assays
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: